Showing results (151-160 of 380) with videos related to
Sort By:
Pageof 38
Leukemia & Lymphoma|October 4, 2017
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage settingPrajwal Boddu, Abdul Rashid Shah, Gautam Borthakur, et al.British Journal of Haematology|October 15, 2014
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosisNaval Daver, Hagop Kantarjian, Guido Marcucci, et al.Leukemia Research|May 14, 2024
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPNGuillermo Montalban-Bravo, Elias Jabbour, Kelly Chien, et al.Cancer Chemotherapy and Pharmacology|April 17, 2020
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutationBin Fan, David Dai, Courtney D DiNardo, et al.American Journal of Hematology|April 6, 2022
Prediction of survival with intensive chemotherapy in acute myeloid leukemiaKoji Sasaki, Farhad Ravandi, Tapan Kadia, et al.Journal for Immunotherapy of Cancer|July 30, 2021
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AMLShelley Herbrich, Natalia Baran, Tianyu Cai, et al.American Journal of Hematology|December 31, 2013
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapyElias Jabbour, Naval Daver, Richard Champlin, et al.The Lancet. Haematology|December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 studyCourtney D DiNardo, Naval Daver, Elias Jabbour, et al.American Journal of Hematology|October 30, 2021
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapyKoji Sasaki, Tapan Kadia, Kebede Begna, et al.Biochimica Et Biophysica Acta. Molecular Cell Research|April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironmentPeter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.Pageof 38